About BioCryst Pharmaceuticals, Inc.
https://www.biocryst.comBioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
CEO
Jon P. Stonehouse
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 145
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
B of A Securities
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:21.79M
Value:$147.74M
BLACKROCK, INC.
Shares:21.25M
Value:$144.05M
BLACKROCK INC.
Shares:19.96M
Value:$135.3M
Summary
Showing Top 3 of 337
About BioCryst Pharmaceuticals, Inc.
https://www.biocryst.comBioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $159.4M ▼ | $127.28M ▼ | $12.9M ▲ | 8.09% ▲ | $0.06 ▲ | $32.13M ▲ |
| Q2-2025 | $163.35M ▲ | $130.77M ▲ | $5.08M ▲ | 3.11% ▲ | $0.02 ▲ | $28.4M ▲ |
| Q1-2025 | $145.53M ▲ | $119.74M ▼ | $32K ▲ | 0.02% ▲ | $0 ▲ | $24.58M ▲ |
| Q4-2024 | $131.53M ▲ | $129.91M ▲ | $-26.8M ▼ | -20.37% ▼ | $-0.13 ▼ | $-1.23M ▼ |
| Q3-2024 | $117.08M | $106.17M | $-14.03M | -11.99% | $-0.07 | $11.69M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $212.87M ▼ | $446.42M ▼ | $834.31M ▼ | $-387.89M ▲ |
| Q2-2025 | $260.04M ▼ | $457.19M ▼ | $878.78M ▼ | $-421.59M ▲ |
| Q1-2025 | $295.38M ▼ | $480.05M ▼ | $931.97M ▼ | $-451.93M ▲ |
| Q4-2024 | $321.06M ▼ | $490.42M ▼ | $966.35M ▲ | $-475.93M ▼ |
| Q3-2024 | $330.83M | $491.25M | $959.82M | $-468.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $12.9M ▲ | $41.11M ▼ | $13.57M ▼ | $-58.3M ▲ | $-3.87M ▲ | $39.77M ▼ |
| Q2-2025 | $5.08M ▲ | $41.3M ▲ | $29.13M ▲ | $-73.69M ▼ | $-16.96M ▼ | $41.12M ▲ |
| Q1-2025 | $32K ▲ | $-27.52M ▼ | $27.09M ▲ | $529K ▲ | $558K ▼ | $-27.66M ▼ |
| Q4-2024 | $-26.8M ▼ | $-5.21M ▼ | $17.8M ▲ | $-4.02M ▼ | $7.26M ▼ | $-5.89M ▼ |
| Q3-2024 | $-14.03M | $8.24M | $8.49M | $1.27M | $18.86M | $8.19M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaborative and Other Research and Development | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $240.00M ▲ | $160.00M ▼ | $140.00M ▼ | $160.00M ▲ |
CEO
Jon P. Stonehouse
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 145
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
B of A Securities
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:21.79M
Value:$147.74M
BLACKROCK, INC.
Shares:21.25M
Value:$144.05M
BLACKROCK INC.
Shares:19.96M
Value:$135.3M
Summary
Showing Top 3 of 337